(MINNEAPOLIS, Minn.) August 4, 2024 – Fasikl presented results from the pilot study of its Felix TM NeuroAI TM Wristband in patients with Essential Tremor at the 3rd Annual Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress held by the Parkinson & Movement Disorder (PMD) Alliance in Washington, DC, in June 2024.
FelixTM NeuroAITM Wristband is a noninvasive, closed-loop, transcutaneous neurostimulation system being developed for essential tremor (ET), one of the most common movement disorders in the US[1]. Using a proprietary AI algorithm, Felix delivers tailored and dynamic treatment, providing full-day tremor relief.
At ATMRD, Fasikl presented the results from a prospective, open-label, two-center pilot study designed to evaluate the safety and effectiveness of the Felix device in ET patients. Patients underwent baseline scoring off and on stim in the office, then use the device at home all day for up to 10 days. The study outcomes showed that Felix is a safe and effective treatment option for ET.
The study won the best poster award at ATMRD and was featured in an interview by NeurolgyLive:
[1] International Essential Tremor Foundation (https://essentialtremor.org)